Dermatology is shifting from surface-level cosmetics to biology-driven interventions targeting aging hallmarks, with senolytics, epigenetic reprogramming, and biomimetic peptides leading the charge. D...
DeepStrataAge, a deep-learning epigenetic clock, reveals sex-specific aging phases through non-linear DNA methylation patterns, enhancing personalized health interventions and clinical applications in...
ARPA-H’s PROSPR program directs over $50 million to aging trials, advancing drugs like Cambrian’s rapamycin analog and Linnaeus’s GPER-targeter, signaling a shift in treating aging a...
In 2025, aging research sees major advancements with senolytics and mitochondrial therapies, backed by clinical trials and shifting medical attitudes towards treating aging as a condition. Recent tria...